Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial

Abstract Background Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. Recent randomize...

Full description

Bibliographic Details
Main Authors: Farsad Eskandary, Michael Dürr, Klemens Budde, Konstantin Doberer, Roman Reindl-Schwaighofer, Johannes Waiser, Markus Wahrmann, Heinz Regele, Andreas Spittler, Nils Lachmann, Christa Firbas, Jakob Mühlbacher, Gregor Bond, Philipp F. Halloran, Edward Chong, Bernd Jilma, Georg A. Böhmig
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Trials
Subjects:
Antibody-mediated rejection
Clazakizumab
Donor-specific antibody
Interleukin-6
Kidney transplantation
Monoclonal antibody
Online Access:http://link.springer.com/article/10.1186/s13063-018-3158-6

Internet

http://link.springer.com/article/10.1186/s13063-018-3158-6

Similar Items